Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
BIIB [NASD]
Biogen Idec Inc.
IndexS&P 500 P/E39.23 EPS (ttm)7.82 Insider Own0.10% Shs Outstand236.39M Perf Week7.45%
Market Cap72.51B Forward P/E21.79 EPS next Y14.08 Insider Trans5.82% Shs Float236.16M Perf Month-1.87%
Income1.86B PEG2.03 EPS next Q2.56 Inst Own93.10% Short Float1.27% Perf Quarter-1.22%
Sales6.93B P/S10.46 EPS this Y35.60% Inst Trans0.07% Short Ratio1.67 Perf Half Y26.20%
Book/sh36.48 P/B8.41 EPS next Y24.43% ROA16.90% Target Price345.24 Perf Year44.18%
Cash/sh5.17 P/C59.30 EPS next 5Y19.35% ROE23.30% 52W Range194.66 - 358.89 Perf YTD9.72%
Dividend- P/FCF- EPS past 5Y24.10% ROI20.70% 52W High-17.86% Beta1.21
Dividend %- Quick Ratio1.40 Sales past 5Y11.10% Gross Margin87.60% 52W Low51.44% ATR14.07
Employees6850 Current Ratio1.80 Sales Q/Q38.60% Oper. Margin35.90% RSI (14)44.69 Volatility3.37% 4.73%
OptionableYes Debt/Eq0.07 EPS Q/Q56.10% Profit Margin26.90% Rel Volume2.56 Prev Close306.75
ShortableYes LT Debt/Eq0.07 EarningsApr 23 BMO Payout0.00% Avg Volume1.81M Price294.80
Recom2.00 SMA20-0.50% SMA50-7.85% SMA2009.47% Volume1,011,081 Change-3.90%
19-Mar-14Reiterated Stifel Buy $360 → $376
07-Mar-14Reiterated Barclays Overweight $325 → $352
03-Mar-14Reiterated Stifel Buy $330 → $360
30-Jan-14Reiterated UBS Neutral $300 → $310
30-Jan-14Reiterated Brean Capital Buy $293 → $377
30-Jan-14Reiterated Argus Buy $310 → $360
28-Jan-14Reiterated Deutsche Bank Buy $340 → $415
27-Jan-14Reiterated Canaccord Genuity Buy $291 → $355
16-Jan-14Reiterated Stifel Buy $296 → $321
10-Jan-14Reiterated Barclays Overweight $285 → $325
20-Dec-13Reiterated RBC Capital Mkts Outperform $275 → $325
12-Dec-13Reiterated Argus Buy $280 → $310
30-Oct-13Initiated FBR Capital Mkt Perform $259
29-Oct-13Reiterated Barclays Overweight $240 → $262
17-Jul-13Reiterated Barclays Overweight $220 → $240
09-May-13Reiterated MKM Partners Neutral $208 → $215
29-Apr-13Reiterated Argus Buy $195 → $250
26-Apr-13Reiterated Canaccord Genuity Buy $206 → $231
26-Apr-13Reiterated Barclays Overweight $210 → $220
23-Apr-13Reiterated Deutsche Bank Buy $170 → $240
24-Apr-14 09:32AM  Earnings Roundup: Biogen's Tecfidera Wins More Share at Motley Fool
09:14AM  Stock Market News for April 24, 2014 Zacks
23-Apr-14 11:44PM  Here's why the biotech bounce may be short lived Talking Numbers
10:54PM  Biogen Idec's CEO Discusses Q1 2014 Earnings Results - Earnings Call Transcript at Seeking Alpha
08:45PM  Biotechnology Stocks To Keep on the Radar at Investopedia
06:46PM  Biogen Q1, Guidance Strong, But Stock Slips at Investor's Business Daily
05:19PM  US STOCKS-Wall St snaps six-day run; Apple to split stock Reuters
04:38PM  US STOCKS-Wall St slips to snap six-day rally; biotechs weak Reuters
03:38PM  Biogen raises outlook as new MS drug again tops forecasts Reuters
03:33PM  [video] Biogen barreling down on Alzheimer's at CNBC
01:55PM  Why Biogen (BIIB) Stock Is Down Today at TheStreet
12:40PM  Biogen's Q1 Earnings Soar Y/Y on Tecfidera Sales Zacks
12:20PM  Midday movers: Facebook, Gilead Sciences & More at CNBC
11:37AM  Biotech ETF Loses Ground as Earnings Disappoint at Barrons.com
11:05AM  Interesting BIIB Put And Call Options For June 21st at TheStreet
10:34AM  Biogen Idec: After Earnings Miss, Pipeline Key to Success at Barrons.com
10:11AM  Biogen Q1 Sales Beat Street, Guidance Strong at Investor's Business Daily
10:04AM  [video] Tech & biotech plays for your portfolio at CNBC
09:24AM  Biogen raises outlook as new MS drug again tops forecasts Reuters
09:21AM  Biogen raises forecast as 1Q profit climbs 12 pct AP
09:08AM  [video] Cramer: Gilead crux of health care in US at CNBC
08:40AM  Amgen's Q1 Earnings Decline Y/Y Zacks
08:00AM  Biogen Idec Inc. Earnings Call scheduled for 8:00 am ET today CCBN
07:43AM  Stocks to watch: T, BA, PG, DAL, BIIB, AAPL, FB Hot Stock Minute
07:43AM  Earnings rush; Apple and Facebook earnings preview; Billionaires under 40 Hot Stock Minute
07:33AM  [$$] Biogen Idec Profit Rises 12% at The Wall Street Journal
07:17AM  Biogen posts higher profit as new MS drug again tops forecasts Reuters
07:16AM  Biogen Profit Increases on Multiple Sclerosis Drug Sales at Bloomberg
07:07AM  BIOGEN IDEC INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q1 2014 Biogen Idec Inc. Earnings Release - Before Market Open CCBN
07:00AM  Biogen Idec First Quarter 2014 Revenues Reach $2.1 Billion Driven by Continued Strength of MS Franchise Business Wire
06:54AM  Why Biogen Idec (BIIB) Might Surprise This Earnings Season Zacks
05:00AM  'Fast Money' Recap: Riding the Momentum at TheStreet
01:58AM  Revance Therapeutics (RVNC) Soars: Stock Up 25.8% Zacks
22-Apr-14 06:04PM  Market shift could drive further advance: Cramer at CNBC
05:40PM  [video] Biogen Idec has room to run: Pro at CNBC
05:05PM  Is Biogen (BIIB) Poised to Beat Earnings Estimates? Zacks
03:45PM  Sarepta Soars on Eteplirsen Submission Plans Zacks
03:01PM  Scouring the moonscape for leading stocks at MarketWatch
01:07PM  [video] Biggest biotech players at CNBC
10:52AM  Keep an Eye on these 3 Biotech Stocks Zacks
10:15AM  Insider Trading Alert - BIIB, JAZZ And KWK Traded By Insiders at TheStreet
06:38AM  Should You Get Rid of Retrophin (RTRX) Now? Zacks
01:52AM  Cytokinetics, Incorporated (CYTK) Jumps: Stock Up 13.5% Zacks
12:43AM  ANI Pharmaceuticals, Inc. (ANIP) Looks Strong: Stock Soars 20.7% Zacks
21-Apr-14 06:34PM  What to Watch for in Biotech Earnings This Week at Motley Fool
05:20PM  Will Amgen (AMGN) Miss This Earnings Season? Zacks
04:46PM  Ackman, Valeant pursuing takeover of Allergan at CNBC
03:54PM  [video] Earnings crystal ball at CNBC
02:34PM  Biotech Is Not A Popping Bubble: Buy The Dip While You Can at Seeking Alpha
02:09PM  Another Technical Look at the Big Biotech ETF ETF Trends
12:20PM  Can Gilead's Sovaldi rescue biotech? at CNBC
08:16AM  Biogen signs Factor VIII license agreement with Amunix theflyonthewall.com
08:00AM  Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII Marketwired
19-Apr-14 03:24AM  [$$] Preview at Barrons.com
18-Apr-14 03:04PM  Exclusive: Biogen prices hemophilia drug on par with older therapies Reuters
12:12PM  Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings at Investor's Business Daily
17-Apr-14 08:31PM  Xenoport's Path Is Long, But The Potential Is There at Seeking Alpha
11:34AM  AbbVie Candidate in Pivotal Study Zacks
09:32AM  Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc. at Motley Fool
09:18AM  Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings at TheStreet
16-Apr-14 09:31AM  3 Biotech Opportunities Following This Selloff at Motley Fool
05:00AM  'Fast Money' Recap: Impressed by Yahoo! at TheStreet
15-Apr-14 05:26PM  Health Care Stocks: Check Out This Low-Cost Market Beater at Motley Fool
02:12PM  Biotech Bubble Bust: 2 Ways to Win at Motley Fool
12:40PM  [video] Love biotech on correction: Trader at CNBC
12:37PM  [video] Top biotech analyst forecasts bottom at CNBC
12:04PM  [video] How to trade momentum stocks at CNBC
10:40AM  Stocks: Thin Gains; Yellen Coaxes Banks To Fortify at Investor's Business Daily
10:27AM  Are Biotechs Bad Medicine for the S&P 500? at Motley Fool
08:31AM  Is Biogen A Value Stock Yet? at Seeking Alpha
12:01AM  U.S. healthcare usage and spending resumes rise in 2013 -report Reuters
14-Apr-14 06:15PM  [video] The IPO plague at CNBC
02:58PM  Biotechs in the green after last week's carnage at CNBC
01:10PM  Biotechs in the green after last week's carnage at CNBC
10:30AM  Gilead Bucks Biotech Trend Thanks to Sovaldi News Zacks
09:00AM  Will Johnson & Johnson (JNJ) Miss This Earnings Season? Zacks
07:30AM  Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting Business Wire
11-Apr-14 07:52PM  Why Biogen Idec Inc., Vertex Pharmaceuticals Incorporated, and Broadcom Corp. Are Todays 3 Worst Stocks at Motley Fool
07:05PM  IPO Frenzy Freezes As Four New Issues Fail To Debut Friday Investor's Business Daily
05:26PM  [video] Fast Money Final Trade: TM, GLNG, YHOO, BIIB at CNBC
05:15PM  [video] Biotech's breakdown at CNBC
04:55PM  Stocks Hit Again; Nasdaq Ends Below 4000 at Investor's Business Daily
04:36PM  Herbalife sinks on probe fears; Zoes surges on debut at MarketWatch
01:45PM  Your first trade for Monday at CNBC
09:34AM  Market selloff: is this the beginning of a correction? Hot Stock Minute
08:58AM  STOCKS TO WATCH: JPM, WFC, HRB, GPS, ALXN, BIIB, NFLX Hot Stock Minute
08:42AM  [video] Here's what's pushing biotech lower: Expert at CNBC
07:54AM  Stock futures lower after J.P. Morgan earnings, Nasdaq's worst day since 2011; Is this the start of a correction? Hot Stock Minute
12:06AM  This is the make-or-break level for biotech Talking Numbers
10-Apr-14 06:49PM  Hemophilia drug draws plaudits Investor's Business Daily
05:00PM  Nasdaq plunges 3%; Dow closes down 267 points at USA TODAY
04:46PM  Nasdaq plunges 3%; Dow closes down 267 points at USA TODAY
04:18PM  Stocks crushed as previous days gains wiped out Hot Stock Minute
04:15PM  Nasdaq plunges 3%; Dow closes down 267 points at USA TODAY
04:02PM  Biotech IPOs Adamas, Cerulean Slump In Trading Debut at Investor's Business Daily
03:53PM  Is the robust IPO market affecting the broader indices? at TheStreet
02:58PM  Software, Biotech, Solar Names Weigh on Nasdaq at Investor's Business Daily
01:22PM  Sellers Dictate Action As Growth Stocks Tumble Again at Investor's Business Daily
12:45PM  Midday movers: Netflix, Tesla Motors, CBS & More at CNBC
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holtzman Steven HEVP Corporate DevelopmentApr 17Sale291.001,221355,3116,970Apr 21 05:07 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,677Apr 03 04:27 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale308.422,123654,77626,142Apr 02 04:16 PM
Posner Brian SDirectorMar 31Sale296.763,000890,2756,435Apr 01 04:15 PM
DORSA CAROLINEDirectorMar 20Option Exercise53.6410,000536,40024,468Mar 21 04:17 PM
DORSA CAROLINEDirectorMar 20Sale348.8810,0003,488,81314,468Mar 21 04:17 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentMar 19Sale352.293,5051,234,7767,976Mar 21 04:15 PM
Holtzman Steven HEVP Corporate DevelopmentMar 17Sale334.831,221408,8278,191Mar 18 05:08 PM
Kingsley Stuart AEVP, Global Comm. OperationsMar 11Sale336.838,4282,838,7663,511Mar 12 07:15 PM
SCANGOS GEORGE AChief Executive OfficerMar 10Sale333.7726,1248,719,37828,265Mar 12 07:20 PM
LEAMING NANCYDirectorMar 10Sale327.652,000655,3007,660Mar 12 07:16 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 04Sale342.583,1711,086,32115,407Mar 05 03:12 PM
SCANGOS GEORGE AChief Executive OfficerMar 03Sale335.792,942987,89454,389Mar 04 03:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 26Sale342.171,048358,59421,407Feb 27 04:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 23Option Exercise0.001,988023,395Feb 25 02:21 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 23Option Exercise0.002,598026,706Feb 25 02:17 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.004,280017,473Feb 25 02:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.003,821023,930Feb 25 02:07 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 18Sale327.901,222400,6949,412Feb 19 04:23 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 13Sale316.42425134,47821,407Feb 14 04:42 PM
SCANGOS GEORGE AChief Executive OfficerFeb 13Sale316.81486153,97057,331Feb 14 04:37 PM
DiPietro KennethEVP Human ResourcesFeb 13Sale316.811,290408,6850Feb 14 04:36 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.002,246012,998Feb 14 04:33 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.003,573013,166Feb 14 04:48 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.002,807014,517Feb 14 04:46 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.002,142021,119Feb 14 04:43 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.0071401,941Feb 14 04:45 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.00792014,459Feb 14 04:42 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.002,142011,644Feb 14 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.009,189062,150Feb 14 04:37 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.002,24602,246Feb 14 04:36 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.003150690Feb 14 04:38 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.002,246025,167Feb 14 04:34 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 11Sale314.312,085655,33613,667Feb 12 05:03 PM
SCANGOS GEORGE AChief Executive OfficerFeb 11Sale314.312,456771,94552,961Feb 12 05:00 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833064,297Feb 11 07:55 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270050,314Feb 11 07:55 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,824011,613Feb 11 07:52 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691013,922Feb 11 07:49 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,346Feb 11 07:43 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691025,133Feb 11 06:07 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909020,723Feb 11 06:07 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,636011,032Feb 11 07:52 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191010,278Feb 11 07:49 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468011,229Feb 11 07:47 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,705010,778Feb 11 07:45 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277014,944Feb 11 07:43 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023021,883Feb 11 06:07 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498017,633Feb 11 06:07 PM
DiPietro KennethEVP Human ResourcesFeb 04Sale299.011,655494,8620Feb 05 04:36 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 03 05:29 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,15909,730Feb 03 05:25 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 01Option Exercise0.004,586010,097Feb 03 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,159010,044Feb 03 05:15 PM
Rowinsky Eric KDirectorJan 21Sale310.092,020626,38210,440Jan 22 04:49 PM
YOUNG WILLIAMDirectorJan 08Sale285.1115,0004,276,59018,509Jan 09 04:24 PM
PANGIA ROBERT WDirectorJan 06Option Exercise47.556,250297,18820,253Jan 07 12:22 PM
PANGIA ROBERT WDirectorJan 06Sale278.036,2501,737,68814,003Jan 07 12:22 PM
SHERWIN STEPHEN ADirectorJan 02Option Exercise59.825,500329,0109,460Jan 06 11:19 AM
SHERWIN STEPHEN ADirectorJan 02Sale279.285,5001,536,0593,960Jan 06 11:19 AM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale285.90439125,51013,667Dec 05 02:53 PM
SCHENK LYNNDirectorDec 02Sale291.711,000291,7104,100Dec 02 03:28 PM
Pawlicki RaymondSVP, Chief Information OfficerNov 22Option Exercise49.954,000199,80012,710Nov 25 02:11 PM
Pawlicki RaymondSVP, Chief Information OfficerNov 22Sale288.004,0001,152,0008,710Nov 25 02:11 PM
SCHENK LYNNDirectorNov 01Sale245.001,000245,0005,100Nov 05 12:18 PM
SCANGOS GEORGE AChief Executive OfficerNov 01Sale245.572,239549,83139,044Nov 05 12:13 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerOct 22Option Exercise60.5615,030910,21729,530Oct 23 05:03 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerOct 22Sale250.1115,0303,759,12314,500Oct 23 05:03 PM
SCHENK LYNNDirectorOct 01Sale242.851,000242,8506,100Oct 02 05:09 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale242.852,239543,74141,283Oct 02 04:35 PM
DiPietro KennethEVP Human ResourcesSep 30Sale242.001,440348,4800Oct 02 01:36 PM
Clancy Paul JExecutive VP and CFOSep 18Option Exercise49.6526,7851,329,87533,872Sep 19 02:14 PM
Clancy Paul JExecutive VP and CFOSep 18Sale245.0026,7856,562,3257,087Sep 19 02:14 PM
Pawlicki RaymondSVP, Chief Information OfficerSep 16Option Exercise49.594,000198,36012,710Sep 18 04:26 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerSep 16Option Exercise49.659,820487,56324,320Sep 18 04:28 PM
Clancy Paul JExecutive VP and CFOSep 16Option Exercise56.1199,0305,556,89551,027Sep 18 04:34 PM
Clancy Paul JExecutive VP and CFOSep 16Sale238.2799,03023,596,3117,087Sep 18 04:34 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerSep 16Sale240.109,8202,357,82114,500Sep 18 04:28 PM
Pawlicki RaymondSVP, Chief Information OfficerSep 16Sale238.034,000952,1208,710Sep 18 04:26 PM
SCHENK LYNNDirectorSep 11Sale235.25900211,7263,325Sep 13 02:33 PM
SCANGOS GEORGE AChief Executive OfficerSep 03Sale214.402,239480,04243,522Sep 04 04:52 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentAug 26Sale211.354,368923,1684,571Aug 28 12:30 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale218.822,239489,93845,761Aug 02 10:55 AM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale223.942,239501,40248,000Jul 18 11:24 AM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339070,250Jul 16 06:19 PM
DENNER ALEXANDER JDirectorJun 14Sale212.002,900614,8006,325Jun 17 03:46 PM
PAPADOPOULOS STELIOSDirectorJun 11Sale219.622,020443,63212,930Jun 13 04:27 PM
Posner Brian SDirectorJun 11Sale219.622,020443,6328,130Jun 13 04:23 PM
SCHENK LYNNDirectorJun 10Sale225.822,000451,6332,920Jun 11 03:55 PM
SHERWIN STEPHEN ADirectorJun 03Option Exercise59.8212,825767,19215,480Jun 04 03:26 PM
SCANGOS GEORGE AChief Executive OfficerJun 03Sale234.161,598374,18848,911Jun 04 03:29 PM
SHERWIN STEPHEN ADirectorJun 03Sale233.2612,8252,991,6052,655Jun 04 03:26 PM
Mulligan RichardDirectorMay 29Option Exercise53.433,000160,2905,020May 31 12:27 PM
DENNER ALEXANDER JDirectorMay 29Option Exercise53.433,000160,2907,920May 31 12:26 PM
DENNER ALEXANDER JDirectorMay 28Option Exercise53.4337,9752,029,00439,920May 29 05:15 PM
Mulligan RichardDirectorMay 28Option Exercise53.4337,9752,029,00437,020May 29 05:16 PM
DENNER ALEXANDER JDirectorMay 28Sale240.5737,9759,135,6974,920May 29 05:15 PM
Mulligan RichardDirectorMay 28Sale240.6937,9759,140,1002,020May 29 05:16 PM
PANGIA ROBERT WDirectorMay 28Sale237.235,9001,399,65712,698May 29 05:12 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise0.003470489May 03 03:10 PM